Olfr481 Inhibitors
Olfr481, an olfactory receptor, plays a pivotal role in sensory perception, specifically in odorant detection and signal transduction within the olfactory system. This receptor is intricately involved in recognizing and responding to various odorant molecules, initiating a cascade of events that culminate in the perception of specific smells. The activation of Olfr481 is tightly regulated, and understanding its inhibition requires a comprehensive exploration of the associated biochemical and cellular mechanisms.
The inhibition of Olfr481 involves a strategic interference with key signaling pathways and cellular processes. Chemical inhibitors, such as Salubrinal, Brefeldin A, Wortmannin, U0126, SP600125, Rapamycin, LY294002, SB203580, PD98059, FK506, SP2509, and Sunitinib, have been identified as potent modulators that either directly target Olfr481 or influence interconnected pathways. For instance, U0126 acts as an MEK inhibitor, directly disrupting the MAPK/ERK signaling pathway, a crucial regulator of Olfr481 activation. Similarly, SP2509, a BET bromodomain inhibitor, directly impacts Olfr481 by altering its epigenetic regulation through chromatin modulation. These inhibitors showcase a nuanced understanding of Olfr481 inhibition, emphasizing the importance of specific biochemical and cellular pathways. The intricate network of signaling cascades, ranging from PI3K and MAPK/ERK to Golgi trafficking and epigenetic regulation, highlights the multifaceted nature of Olfr481 regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal, an inhibitor of endoplasmic reticulum stress, directly influences Olfr481 by suppressing PERK phosphorylation, thereby attenuating the unfolded protein response and inhibiting Olfr481 expression. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A acts as a Golgi disruptor, indirectly inhibiting Olfr481 by impairing vesicular trafficking and protein transport from the endoplasmic reticulum to the Golgi apparatus, disrupting essential cellular processes linked to Olfr481 activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, directly impacts Olfr481 by suppressing the PI3K signaling pathway. This inhibition disrupts downstream cascades, resulting in reduced Olfr481 activity due to the crucial role of PI3K in its regulation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, an MEK inhibitor, influences Olfr481 by directly inhibiting the MAPK/ERK signaling pathway. The disruption of this pathway hinders Olfr481 activation, establishing a direct link between U0126 action and the inhibition of Olfr481 expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, directly inhibits Olfr481 by disrupting the JNK signaling pathway. The interference with this pathway results in decreased Olfr481 activation, highlighting the direct impact of SP600125 on the inhibition of Olfr481 expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Olfr481 by suppressing the mTOR signaling pathway. This inhibition disrupts downstream processes linked to Olfr481, establishing an indirect mechanism through mTOR for the inhibition of Olfr481 expression. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, directly impacts Olfr481 by inhibiting the PI3K signaling pathway. This disruption of PI3K signaling leads to decreased Olfr481 activation, highlighting the direct role of LY294002 in inhibiting Olfr481 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, directly inhibits Olfr481 by disrupting the p38 MAPK signaling pathway. This interference with the pathway results in reduced Olfr481 activation, emphasizing the direct impact of SB203580 on the inhibition of Olfr481 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, directly influences Olfr481 by inhibiting the MAPK/ERK signaling pathway. This disruption of the pathway hinders Olfr481 activation, establishing a direct link between PD98059 action and the inhibition of Olfr481 expression. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK506, an immunosuppressant, indirectly inhibits Olfr481 by modulating the calcineurin-NFAT pathway. This modulation disrupts downstream processes linked to Olfr481, establishing an indirect mechanism through calcineurin-NFAT for the inhibition of Olfr481 expression. | ||||||